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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed tumors worldwide and is known to
be resistant to conventional chemotherapy. New therapeutic strategies are urgently needed for treating HCC. Osthole, a
natural coumarin derivative, has been shown to have anti-tumor activity. However, the effects of osthole on HCC have not
yet been reported.
Methods and Findings: HCC cell lines were treated with osthole at various concentrations for 24, 48 and 72 hours. The
proliferations of the HCC cells were measured by MTT assays. Cell cycle distribution and apoptosis were determined by flow
cytometry. HCC tumor models were established in mice by subcutaneously injection of SMMC-7721 or Hepa1-6 cells and
the effect of osthole on tumor growths in vivo and the drug toxicity were studied. NF-kB activity after osthole treatment was
determined by electrophoretic mobility shift assays and the expression of caspase-3 was measured by western blotting. The
expression levels of other apoptosis-related genes were also determined by real-time PCR (PCR array) assays. Osthole
displayed a dose- and time-dependent inhibition of the HCC cell proliferations in vitro. It also induced apoptosis and caused
cell accumulation in G2 phase. Osthole could significantly suppress HCC tumor growth in vivo with no toxicity at the dose
we used. NF-kB activity was significantly suppressed by osthole at the dose- and time-dependent manner. The cleaved
caspase-3 was also increased by osthole treatment. The expression levels of some apoptosis-related genes that belong to
TNF ligand family, TNF receptor family, Bcl-2 family, caspase family, TRAF family, death domain family, CIDE domain and
death effector domain family and CARD family were all increased with osthole treatment.
Conclusion: Osthole could significantly inhibit HCC growth in vitro and in vivo through cell cycle arrest and inducing
apoptosis by suppressing NF-kB activity and promoting the expressions of apoptosis-related genes.
Citation: Zhang L, Jiang G, Yao F, He Y, Liang G, et al. (2012) Growth Inhibition and Apoptosis Induced by Osthole, A Natural Coumarin, in Hepatocellular
Carcinoma. PLoS ONE 7(5): e37865. doi:10.1371/journal.pone.0037865
Editor: Dermot Cox, Royal College of Surgeons, Ireland
Received January 29, 2012; Accepted April 25, 2012; Published May 25, 2012
Copyright:  2012 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work has been supported in part by the research funds from Jiangsu Province Administration of Traditional Chinese Medicine, grants from
National Natural Science Foundation of China (91029703), the funding for the key laboratory of Suzhou city (SWG0904 and SS201032), Priority Academic Program
Development of Jiangsu Higher Education Institutions, and Program for Changjiang Scholars and Innovative Research Team in University (IRT1075). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hliu@suda.edu.cn (HL); guorongjiang@hotmail.com (GJ)
Introduction
Hepatocellular carcinoma (HCC) is the most common primary
malignant tumor of the liver and accounts for about 5.6% of all
tumors [1]. Because of its poor prognosis, it is the third most
common cause of cancer mortality [2,3,4]. HCC is highly
aggressive and resistant to conventional therapies such as
radiotherapy and chemotherapy [5,6,7]. Therefore, more effective
therapeutic agents for treating HCC are desirable.
Previous studies have shown that some natural chemopreventive
agents can induce apoptosis of tumor cells and inhibit tumor
growth, including HCC, both in vitro and in vivo
[8,9,10,11,12,13,14]. Because of their selectivity of killing tumor
cells and minimal toxicity comparing with conventional chemo-
therapies, they are becoming promising approaches for tumor
treatments. Coumarins and its known metabolite 7-hydroxy-
coumarin have been shown to have growth suppressive effect on
many cancer cell lines, such as colon-carcinoma cell lines,
hepatocellular carcinoma cell lines, leukemia cell lines, melanoma
cell lines, renal cell carcinoma cell lines and non-small cell lung
carcinoma cell lines [15,16,17]. Auraptene, one of the coumarins,
has been shown to be effective in inhibiting the development of
esophageal tumors and colitis-related colon cancers in animal
models [18,19]. Coumarin has also been used in a clinical trial to
prevent disease recurrence in melanoma patients [20]. They can
affect multiple signaling pathways, such as ERK/MAPK and
PI3K/Akt pathways, which play important roles in carcinogenesis
[17,21,22,23,24].
Osthole, 7-methoxy-8-(3-methyl-2-butenyl) coumarin, a bioac-
tive simple coumarin derivative extracted from many medicinal
plants such as Cnidium monnieri (L.) Cusson, has long been used in
traditional Chinese medicine for the treatment of eczema,
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dysfunction. Recent studies have revealed that osthole has
comprehensive and wider applications with anti-inflammatory,
anti-osteoporotic, anti-bacterial, and anti-allergic effects
[25,26,27,28,29]. Furthermore, accumulating evidence indicates
that osthole possesses anti-tumor effects by inhibiting tumor cell
growth and inducing apoptosis [30,31,32,33]. It has been reported
recently that osthole was able to inhibit the migration and invasion
of breast cancer cells [34]. However, the effects of osthole on HCC
remain unknown.
The molecular mechanism of osthole’s anti-tumor effect was not
yet clearly known. It has been shown that osthole-induced G2/M
arrest and apoptosis in lung cancer A549 cells were associated with
the inhibition of Cyclin B1, p-Cdc2 and p-Akt expressions and up-
regulation of the Bax/Bcl-2 ratios [33]. Osthole could also down-
regulate fatty acid synthase (FASN) expression and induce
apoptosis in HER2-overexpressing breast cancer cells through
inhibiting the phosphorylation of Akt and mTOR [35]. Further-
more, osthole has been shown to effectively inhibit MMP-2
promoter and enzyme activity, which might be one of the causes
that lead to the inhibition of migration and invasion of breast
cancer cells by osthole [34]. More studies are needed to fully
address the molecular mechanisms of the anti-tumor effects of
osthole.
In the present study, osthole was found to inhibit proliferation
and induce apoptosis of HCC cell lines. Osthole treatment
significantly suppressed the tumor growth in nude mice and C57/
BL6 mice. Our results also suggested that osthole could inhibit NF-
kB activity and up-regulate the expression levels of apoptosis-
related genes. Therefore, osthole could be a good compound for
developing anticancer agents for HCC.
Materials and Methods
Cell Lines and Culture Conditions
Human HCC cell line HepG2 and murine HCC cell line
Hepa1-6 were gifts from Dr. Limin Zheng (School of Life
Sciences, Sun Yat-sen University). Human HCC cell line HepG2
was originally purchased from ATCC (Manassas, VA). Hepa1-6
was originally purchased from Cell Bank, Chinese Academy of
Sciences (Shanghai, China). Human HCC cell lines SMMC-7721
and SK-HP-1 were purchased from Cell Bank, Chinese Academy
of Sciences (Shanghai, China). Cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) with high glucose
(Gibco, Grand Island, NY) supplemented with 10% heat-
inactivated fetal bovine serum (Gibco, Grand Island, NY) at
37uC in a humidified atmosphere containing 5% CO2.
Antibodies and Reagents
Antibodies against b-actin and caspase-3 were purchased from
Cell Signaling (Boston, MA). Osthole (molecular weight 244.29)
was purchased from National Institutes for Food and Drug
Control (Beijing, China). Nuclear and Cytoplasmic Protein
Extraction Kit and BCA Protein Assay Kit were purchased from
Beyotime (Jiangsu, China). Annexin V-FITC and PI double
staining kit were purchased from Key Gene (Jiangsu, China). NF-
kB EMSA Kit was purchased from Viagene Biotech (Tampa, FL).
RT
2 Profiler PCR Arrays was purchased from SABiosciences
Corporation (Frederick, MD). Osthole was purchased from
National Institutes for Food and Drug Control (Beijing, China).
It is over 99% pure determined by HPLC. A stock solution of
osthole (205.0 mM) was prepared by dissolving in DMEM with
0.25% ethanol and 0.25% dimethyl sulfoxide (DMSO).
Cell Viability Assay
The effect of osthole on cell viability was measured by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazoliumbromide (MTT) as-
say. The cells were plated at a density of 2.5610
3 per well in 96-
well plates overnight and then treated with different concentra-
tions of osthole (0, 20.5, 41.0, 82.0, 123.0, 164.0 and 205.0 mM).
The final concentrations of DMSO and ethanol were lower than
0.25%. After incubation for 24 h, 48 h and 72 h at 37uCi na
humidified incubator, MTT (5 mg/ml in phosphate buffered
saline (PBS)) was added to each well and incubated for 4 h; then
the medium was totally removed, 0.1 ml of buffered DMSO was
added to each well. The absorbance was recorded on a microplate
reader (Sepctra Max M2e, Molecular Devices, Silicon Valley, CA)
at the wavelength of 490 nm. The effect on cell proliferation was
assessed as the percent cell viability wherein vehicle-treated cells
were taken as 100% viable.
Cell Cycle Analysis
After osthole treatment, the DNA content and cell cycle
distribution of SMMC-7721 and Hepa1-6 cells were determined
by flow cytometry. Cells plated at a density of 5610
5 per well in 6-
well plates were treated with osthole and harvested at 24 h. The
cells were washed once in PBS. They were then fixed in cold 70%
ethanol and stored at 4uC for 30 min. Then ethanol was removed
and the cells were resuspended in PBS. The fixed cells were then
washed with PBS, treated with RNase (100 mg/ml), and stained
with Propidium Iodide (PI, 20 mg/ml) in the dark for 30 min at
37uC. Cell cycle was analyzed by flow cytometry (BD Biosciences,
Franklin Lakes, NJ) and analyzed by Flowjo software.
Quantification of Apoptosis
For apoptosis analysis, SMMC-7721 and Hepa1-6 cells (5610
5)
were plated in each well of the 6-well plates and treated with
different doses (0, 41.0, 82.0, 123.0, 164.0 and 205.0 mM) of
osthole in 10% fetal bovine serum- DMEM for 48 h. The cells
were then labeled with Annexin V and Propidium Iodide (PI) (Key
Gene, JiangSu, China). Apoptotic rates were determined by flow
cytometry (BD Biosciences, Franklin Lakes, NJ) and analyzed by
Flowjo software. The percentage of the early apoptosis was
calculated by Annexin V-positivity and PI-negativity, while the
percentage of the late apoptosis was calculated by Annexin V-
positivity and PI-positivity.
Animal Studies
A total of 2610
6 SMMC-7721 cells (or Hepa1-6 cells)
suspended in 0.2 ml PBS were inoculated subcutaneously (s.c.)
into the right flank of 50 nude mice (or C57/BL6 mice) using 1-ml
needles. A week later, the mice were randomly distributed into five
groups and each group consisted of 10 mice. They were treated
with 244 mg/kg (1.0 mmol/kg), 122 mg/kg (0.5 mmol/kg) and
61 mg/kg (0.25 mmol/kg) osthole intraperitoneally (i.p.) in 0.2 ml
corn oil, with corn oil alone as the control group and cisplatin as
the positive control once every other day for 2 weeks. The tumor
volumes were measured once every three days. The following
formula was used for tumor volume measurement: (short
diameter)
2 * long diameter/2. On day 21, mice were sacrificed
and tumor tissues, spleens and thymus were weighed. The Ethical
Committee of Soochow University specifically approved the
current study.
Western Blot Analysis
SMMC-7721 cells were treated with osthole (0, 41.0, 82.0,
123.0, 164.0 and 205.0 mM) for 48 h in complete cell medium.
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prepared and stored at -80uC for later use. The protein content in
the lysates was determined using BCA Protein Assay Kit
(Beyotime, Jiangsu, China). For Western blot analysis, 50 mgo f
protein from each sample were subjected to separate on a SDS-
PAGE gel. After electrophoresis, proteins were electroblotted to
polyvinylidene difluoride (PVDF) membranes, and subsequently
incubated in blocking buffer (5% nonfat dry milk) for 12 h at 4uC.
The blots were incubated with appropriate primary antibody,
washed, and incubated with horseradish peroxidase (HRP)-
conjugated secondary antibody (Dako, Carpinteria, CA). The
blots were detected with chemiluminescence (ECL-Kit, Beyotime,
JiangSu, China) followed by autoradiography. Equal loading of
protein was confirmed by stripping the blots and reprobing with b-
actin antibody.
Electrophoretic Mobility Shift Assays (EMSA)
SMMC-7721 cells were plated at a density of 2610
6 per well in
6-well plates with or without osthole treatment and harvested at
12 h, 24 h and 48 h. Nuclear protein of SMMC-7721 cells were
extracted using Nuclear and Cytoplasmic Protein Extraction Kit
(Beyotime, Jiangsu, China) and protein content was determined
using BCA Protein Assay Kit (Beyotime, Jiangsu, China). Nuclear
protein (10 mg) was incubated with 106binding buffer, 1.0 mg/ml
poly(dI-dC), and 0.5 ml biotin-labeled double-stranded NF-kB
binding consensus oligonucleotides 59-AGTTGAGGG-
GACTTTCCCAGGC-39(total volume 15 ml) in an EMSA Kit
(Viagene Biotech, Tampa, FL). The binding reaction was
performed for 25 min at room temperature. The incubation
mixtures were separated by 6.5% non-denaturing PAGE and the
bands were detected by autoradiography.
Real-time PCR
SMMC-7721 cells were plated at a density of 5610
5 per well in
6-well plates with or without osthole (123.0 mM) treatment for
48 h. RNA was extracted from the cells using TRIzol reagent
(Invitrogen, Carlsbad, CA). RNA concentration was determined
by UV spectrophotometry (concentration by A260 should be
greater than 40 mg/ml total RNA). RNA was converted to
cDNAs. The real-time PCR was performed using an RT
2 Profiler
PCR Arrays (SABiosciences, Frederick, MD). Experimental
cocktail was prepared by adding the first strand cDNAs synthesis
reaction (102 ml) to 2X SABiosciences RT
2 qPCR master mix
(1350 ml) and water (1248 ml). Add 25 ml of the experimental
cocktail to each well of the PCR Array. The plates were
centrifuged for 1 minute at room temperature at 1000 g to
remove bubbles. PCR were run with a Biosystems 7500 Fast Real-
Time PCR System (Applied Biosystems, Foster, CA). The thermal
cycle profile was as follows: 15 s at 95uC, 60 s at 60uC for 40
cycles. The data were calculated and analyzed by ggCt.
Statistical Analysis
All data represents at least three independent experiments and
results were shown as mean6SD. Statistical differences between
Figure 1. Osthole Inhibited Cell Proliferation of HCC Cell Lines. (A) Chemical Structure of osthole (B) Viability of SK-HP-1, SMMC-7721, HepG-2
and Hepa1-6 cells treated with osthole. MTT assay was performed to measure cell growth inhibition rate at 48 h after osthole treatment. (C)(D)
Viability of SMMC-7721 and Hepa1-6 cells treated with osthole. MTT assay was performed to measure cell growth inhibition rate at 24 h, 48 h and
72 h after osthole treatment. Data shown were representatives of three experiments.
doi:10.1371/journal.pone.0037865.g001
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difference was considered as p,0.05.
Results
Effect of Osthole on Cell Viability and Apoptosis of HCC
Cell Lines
Chemical structure of osthole was shown in figure 1A. In order
to determine the effects of osthole on HCC, human HCC cell lines
SK-HP-1, SMMC-7721, and HepG-2 and murine HCC cell line
Hepa1-6 were treated with osthole at different doses for 48 h
(Fig. 1B). Osthole treatment inhibited the proliferation of all four
HCC cell lines in a dose-dependent manner. There was no
significant difference in drug sensitivity (IC50: 189.5 mM,
161.9 mM, 161.4 mM and 137.0 mM, respectively) between the
four HCC cell lines. Further experiments showed that osthole
treatment inhibited the proliferation of SMMC-7721 and Hepa1-6
cell lines in a time-dependent manner (Fig. 1C&D).
The effect of osthole on cell cycle distribution was evaluated by
flow cytometry. When osthole was administered at the dose of
123.0 mM, SMMC-7721 and Hepa1-6 cells both exhibited
increased cell percentages in G2 phase (Fig. 2) with an increase
of SMMC-7721 cells from 3.50% to 12.18% and Hepa1-6 cells
from 3.92% to 12.99%. To further investigate whether Osthole
could induce apoptosis of the HCC cells, the apoptotic cell
percentages were analyzed by flow cytometry. SMMC-7721 and
Hepa1-6 cells were treated with different concentrations of osthole
(0, 41.0, 84.0, 123.0, 164.0 and 205.0 mM) for 48 h. The
percentages of apoptotic cells were significantly increased in the
treated group compared to control group (p,0.05) (Fig. 3A&B) for
both cell lines in a dose-dependent manner. The apoptotic cells
increased from total about 10% to 70% for SMMC-7721 cells and
60% for Hapa-1-6 cells. Taken together, osthole treatment could
induce HCC cells apoptosis and G2 phase arrest.
Osthole Suppressed the Tumor Growth in Murine Models
of HCC
In order to determine the tumor suppressive effect of osthole in
vivo, we next examined the effect of osthole in murine models of
HCC. Nude mouse were subcutaneously inoculated with 2610
6
SMMC-7721 cells (day 1). Osthole treatment started on day8 and
was administered at 244 mg/kg, 122 mg/kg and 61 mg/kg,
intraperitoneally for 2 weeks with corn oil as the blank control
and cisplatin (5 mg/kg) as the positive control. The data showed
that tumor development was significantly suppressed in osthole
(244 mg/kg and 122 mg/kg) -treated mice (29614 mm
3,
72632 mm
3) compared with the control group (3106139 mm
3)
(p,0.01) (Fig. 4A). The tumor weights of osthole (244 mg/kg and
122 mg/kg)-treated mice (144.3640.1 mg, 174.0672.8 mg) were
significantly less than those of the control group (402.0651.8 mg)
(p,0.01) (Fig.4B).
Another murine model of HCC was established by subcutane-
ously inoculating 2610
6 Hepa1-6 cells in C57/BL6 mice. The
mice were treated with osthole at 244 mg/kg, 122 mg/kg and
61 mg/kg intraperitoneally for 2 weeks starting on day 8.
Compared with the control group, osthole (244 mg/kg and
122 mg/kg) treatment also significantly suppressed tumor growth
(Fig. 4C) and reduced the tumor weights on day 21 (p,0.05,
Figure 2. Effects of Osthole on Cell Cycle of HCC Cells. Cell cycle analysis of SMMC-7721 and Hepa1-6 cells following 123.0 mM osthole
treatment for 24 h by flow cytometry.
doi:10.1371/journal.pone.0037865.g002
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effective agent that could inhibit the growth of transplanted HCC
tumors in vivo.
There were no difference in body weight in three osthole
treatment groups (23.5062.06 g, 22.9061.29 g, 23.9061.64 g) in
SMMC-7721 model compared with the control group
(23.9061.39 g), but the body weights in cisplatin group
(14.3060.76 g) were significantly decreased (p,0.01) (Fig. 4E).
The Hepa1-6 HCC model showed similar results (data not shown).
Moreover, the weights of spleens and thymus of three osthole
treatment groups (spleens: 117.8634.3 mg, 107.6.617.8 mg,
108.8630.8 mg; thymus: 39.568.3 mg, 38.0.66.6 mg,
38.666.2 mg) showed no difference compared with those of the
control group (spleens: 102.064.9 mg; thymus: 38.4611.0 mg),
while both spleen and thymus weights dropped dramatically in the
cisplatin group (spleens: 32.064.2 mg, p,0.001; thymus:
0.0460.1 mg, p,0.001, Fig. 4F&G). Therefore, osthole exhibited
no apparent sign of toxicity in murine HCC models.
Effects of Osthole on NF-kB Activity, Capase-3 and Other
Apoptotic-related Gene Expressions
To further illustrate the molecular basis of the apoptosis
induction by osthole, we investigated the effect of osthole on
NF-kB activity. In SMMC-7721 cells, osthole significantly
suppressed NF-kB activity in a time- (Fig. 5A) and dose- (Fig. 5B)
dependent manner. The expression levels of caspase-3 after
osthole treatment (0, 41.0, 82.0, 123.0, 164.0 and 205.0 mM) were
also measured in SMMC-7721 cells. The total caspase-3 and the
cleaved caspase-3 levels were both increased with osthole
treatment in a dose-dependent manner (Fig. 5C).
To further demonstrate the effects of osthole on the apoptotic
signaling pathways, we measured the expression levels of a set of
apoptosis-relevant genes with or without osthole treatment in
SMMC-7721 cells using RT
2 Profiler PCR Arrays. The results
showed that most apoptosis-related genes had increased expression
levels with osthole treatment, which belonged to TNF ligand
family, TNF receptor family, Bcl-2 family, caspase family, TRAF
family, death domain family, CIDE domain and death effector
domain family and CARD family (Fig. 6). Most changes were seen
with the genes of the TNF ligand and receptor families. These
results suggested that osthole treatment could induce apoptosis by
up-regulating apoptosis-related gene expressions, especially TNF
ligand and receptor gene expressions.
Discussion
This is the first report on the anti-tumor effect of osthole in
HCC. Our data demonstrated that osthole could inhibit the
proliferation of HCC cell lines in vitro and suppress HCC tumor
growth in vivo. It could down-regulate NF-kB activity and up-
Figure 3. Effects of Osthole on apoptosis of HCC cells. (A) Induction of apoptosis of SMMC-7721 and Hepa1-6 cells after osthole treatment.
SMMC-7721 and Hepa1-6 cells were treated with osthole at doses of 0, 41.0, 84.0, 123.0, 164.0 and 205.0 mM for 48 h. Apoptosis was measured by
flow cytometry. (B) Statistical analysis of the percentages of the apoptotic cells. Data shown were representatives of three experiments.
doi:10.1371/journal.pone.0037865.g003
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osthole could be developed as a novel anti-tumor agent for treating
HCC.
Recently, it has been suggested that osthole could induce G2/M
arrest and apoptosis in lung cancer A549 cells by modulating
PI3K/Akt pathway [33]. Our results also suggested osthole could
induce apoptosis and G2/M arrest in HCC cells. Meanwhile we
demonstrated that osthole could inhibit NF-kB activation. It has
been shown that the activated NF-kB could promote G2/M
transition through inhibiting GADD45 expression following up-
regulating Cyclin B [36]. Prostate cancer cells could be arrested in
G2/M phase and undergo apoptosis by NF-kB inhibition [37].
Therefore, osthole could induce G2/M arrest and apoptosis
through inhibiting NF-kB activity in HCC cells.
Multiple cellular receptors and signaling pathways are involved
in promoting NF-kB activation, which plays a central role in HCC
development, progression, and therapy [38]. It has been shown
that the levels of NF-kB expression are higher in cancer tissues in
HCC [39]. Various methods of HCC intervention, including
proteasome inhibitor, IkB kinase (IKK) gene knockout, IkBa
super-inhibitor, and interfering with NF-kB oligonucleotide or
RNA, indicated that inhibiting the activity of NF-kB could inhibit
the growth of HCC cells [40,41,42,43]. It has been shown that
thalidomide could effectively postpone or hinder the HCC
development through inhibiting NF-kB activation in rat model
[44]. Furthermore, one of the causes for apoptosis- and drug-
resistance to occur in HCC cells was the activation of NF-kB [45].
Our results demonstrated that osthole could inhibit NF-kB activity
in HCC cell lines in a dose- and time-dependent manner.
Therefore, the proliferation inhibition in HCC cell lines by osthole
could be due to its suppressive effect on NF-kB activity.
In nude mouse model of HCC, osthole administered at
244 mg/kg and 122 mg/kg significantly suppressed the growth
of SMMC7721 cell-derived tumors and the similar tumor-
Figure 4. Effect of Osthole Treatment on the Tumorigenicity of HCC Cells. A total of 2610
6 SMMC-7721 or Hepa1-6 cells were inoculated
subcutaneously (s.c.) into the right flank of nude mice or C57/BL6 mice. Mice were randomized into five groups including osthole treatment (244 mg/
kg, 122 mg/kg and 61 mg/kg), corn oil alone as the blank control and cisplatin (5 mg/kg) as the positive control on Day8 and were treated once
every other day for 2 weeks. (A) The tumor volumes of the nude mice inoculated with SMMC-7721 cells were measured and calculated once every
three days. The tumor sizes on day 21 were shown in the inserted figure. (B) Tumor weights of the nude mice inoculated with SMMC-7721 cells were
measured on day21. (C) The tumor volumes of the C57/BL6 mice inoculated with Hepa1-6 cells were measured and calculated once every three days.
(D) Tumor weights of the C57/BL6 mice inoculated with Hepa1-6 cells were measured on day21. (E) The body weights of nude mice inoculated with
SMMC-7721 cells were weighed on day 21. The (F) spleen weights and (G) thymus weights of the C57/BL6 mice inoculated with Hepa1-6 cells were
weighed on day21. Each data point represented the mean6S.D. of 10 mice. Data shown were the representatives of three experiments.
doi:10.1371/journal.pone.0037865.g004
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Hepa1-6 cell-derived tumors. Interestingly, the lower dose of
61 mg/kg did not exhibit significant suppressive effects, which
suggested that a relatively high dose of osthole was required to
achieve therapeutic effects. This may also suggest that it could be
the derivatives of osthole through the liver metabolism that exert
the therapeutic effects on HCC. In both human and murine HCC
models, the body weights of osthole treated groups were not
different from those of the control group. In the immune
competent murine HCC model, the spleen weights and thymus
weights of osthole treated groups were also similar as those of the
control group. Therefore, osthole exhibited no apparent signs of
toxicity in murine HCC models without injuring immune organs.
This also justified the safety of the high dose of osthole required for
treating HCC. However, some coumarins may cause idiosyncratic
hepatotoxicity and this requires further toxicity studies and should
be taken into considerations during clinical trials.
Coumarins have been shown to undergo differential metabo-
lisms in mice, rats and humans [46,47]. The 7-hydroxylation
pathway of coumarin metabolism is the major pathway in human
but is only a minor pathway in the rat and mouse. It is a
detoxification pathway and negatively correlated with the toxicity
in the target organs, such as lung and liver. In contrast, the major
route of coumarin metabolism in the rat and mouse is by a 3,4-
epoxidation pathway resulting in the formation of toxic metabo-
lites. The liver toxicity of coumarins could also lead to tumor
formation in rats and female mice [48]. Therefore, the toxicity and
carcinogenicity of coumarins are expected to be much lower in
humans.
Although some coumarins have been shown to act as immune
stimulants [49], osthole has been shown to have anti-inflammatory
activities [25,50]. It suppressed IL-4-induced eotaxin in BEAS-2B
cells via inhibition of STAT6 expression and might have the
potential for treating allergic airway inflammation [50]. Osthole
could also attenuate the experimental autoimmune encephalomy-
elitis in C57 BL/6 mice and may be used for treating multiple
sclerosis [51]. However, in osthole treated tumor-bearing immune
competent mice, we observed no toxicity on immune organs and
no significant decrease of peripheral or tumor infiltrating T cell
numbers (data not shown). We hypothesize that osthole’s immune
suppressive effect may only act on the activated immune cells. In
tumor-bearing individuals, especially at the late stage of the
disease, the immune system is normally suppressed. Therefore, the
immune-suppressive effect of osthole may only play a minor role
comparing to its anti-tumor effect during the treatment.
Real-time PCR results showed that osthole increased the
mRNA levels of apoptosis-related genes belonged to TNF ligand
family, TNF receptor family, Bcl-2 family, caspase family, TRAF
Figure 5. Effects of Osthole Treatment on Caspase-3 expression and NF-kB activation. (A) SMMC-7721 cells were treated with osthole
(123.0 mM) for 12 h, 24 h and 48 h. The nuclear proteins were prepared and analyzed for NF-kB expression by EMSA. (B) SMMC-7721 cells were
treated with osthole at doses of 0, 41.0, 82.0, 123.0, 164.0 and 205.0 mM for 24 h. The nuclear proteins were prepared and analyzed for NF-kB
expression by EMSA. (C) SMMC-7721 cells were treated with osthole at doses of 0, 41.0, 82.0, 123.0, 164.0 and 205.0 mM for 48 h. The cell lysates were
prepared and analyzed for caspase-3 expression by Western blot analysis. Equal loading was confirmed by stripping immunoblots and reprobing for
b-actin. Data shown were representatives of three experiments. (D) Statistical analysis of caspase-3 quantification. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0037865.g005
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domain family and CARD family. One study reported that osthole
induced apoptosis in A549 cells through down-regulating the
expressions of Bcl-2 and up-regulating the expressions of Bax [33].
However, our data did not show significant changes in Bcl-2 and
Bax expressions (data not shown). On the other hand, the
expression levels of the genes belonged to TNF ligand and TNF
receptor families were up-regulated by osthole treatment. How-
ever, the exact molecular targets and mechanisms of apoptosis
induction by osthole treatment still need further investigations.
Our results provided basis for mechanistic studies of osthole’s anti-
tumor effects in HCC.
Taken together, our results suggested that osthole could
effectively inhibit HCC tumor growth in vitro and in vivo with no
sign of toxicity through, at least in part, suppressing NF-kB
activation and induction of the apoptotic pathways. Therefore, our
results support the notion that osthole could be developed as a
potential agent for treating HCC.
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